William Blair initiated coverage of Aktis Oncology with an Outperform rating. The company is positioned to become a radiopharmaceuticals leader by using miniproteins to address novel targets within the modality, the analyst tells investors in a research note. The firm believes Aktis' approach could allow the company to capture a "material proportion "of the radiopharmaceuticals market, which it estimates to be $35B.
